Yes. Dexamethasone is off-patent and has been marketed in different formulations (e.g., tablets, liquid, solution for injection) for many years. It is generally available in most countries. There are several manufacturers of the product. One manufacturer has already been prequalified by WHO (Kern Pharma in Spain) while another is under assessment.The most common formulations are:Tablets: 0.5mg, 0.75mg, 1mg, 1.5mg, 2mg, 4mg and 6mgOral Solution: 0.5mg/5ml, 20mg/5ml and 1mg/ml (concentrate) Injectable suspension: 4mg/ml, 20mg/5mlIn recent years there have been occasional reports of shortages of this product. It is important to quickly understand the projected volumes for COVID-19 utilization and manufacturing capacity to help assess the impact for existing indications and the potential need for substitute therapies, to ensure all patients retain access to a safe, effective, quality, affordable product to meet their therapeutic needs.
